Voltar
Carta Acesso aberto Revisado por pares
BIBTEX RIS

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma

2008; Lippincott Williams & Wilkins; Volume: 26; Issue: 6 Linguagem: Inglês

10.1200/jco.2007.15.1605

ISSN

1527-7755

Autores

Marc C. Chamberlain,

Tópico(s)

Nanoplatforms for cancer theranostics

Resumo

I congratulate Vredenburgh and colleagues 1 for their article further supporting the role of bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM).This article, an earlier article from the same group, a small series from the University of California, Los Angeles group, and the first report by Stark-Vance of this drug combination all seem to support the thesis that antiangiogenic therapy has substantial activity in recurrent GBM. [1]2][3][4] Several issues regarding the article are relevant and warrant discussion.

Referência(s)